vaccin
strategi
depend
entir
appropri
respons
immun
system
particular
antigen
activ
immun
truli
effect
neutral
antibodi
nab
need
effici
counter
infect
propag
pathogen
virus
includ
hiv
abl
take
advantag
immun
respons
order
evad
nab
review
focus
viral
immun
evas
strategi
result
directli
robust
immun
respons
infect
vaccin
rational
multiab
therapi
circumv
phenomenon
discuss
progress
formul
product
regulatori
approv
monoclon
antibodi
mab
present
persist
hiv
global
epidem
reveal
limit
understand
immun
barrier
function
protect
human
diseas
soon
recognit
hiv
viru
caus
agent
aid
predict
made
vaccin
would
avail
test
within
two
year
interven
year
inabl
creat
effect
protect
therapeut
vaccin
attribut
number
characterist
hiv
characterist
natur
result
evas
immun
surveil
also
util
virus
viral
evas
gener
involv
accumul
point
mutat
immunedomin
region
surfac
protein
glycosyl
function
pivot
residu
glycan
shield
associ
host
serum
compon
eg
lipoprotein
order
mask
immun
system
celltocel
transmiss
addit
molecular
mimicri
wherebi
express
protein
structur
similar
host
defens
protein
lead
viral
persist
strategi
turn
result
damag
effect
secondari
consequ
molecular
mimicri
rang
viralinduc
autoimmun
diseas
chronic
immun
stimul
exampl
hcvinduc
cryoglobulinemia
particular
case
hiv
immun
evas
result
varieti
addit
strategi
incred
sequenc
divers
within
hiv
subtyp
well
within
individu
cours
activ
infect
repres
enorm
challeng
immun
system
furthermor
hiv
attack
cell
need
mount
effect
coordin
immun
respons
destruct
cell
facilit
viral
replic
addit
evas
strategi
involv
downregul
mhc
molecul
establish
latent
viral
genom
result
product
infecti
viru
perhap
year
later
well
high
mutat
rate
viral
genom
result
infecti
virus
immun
respons
recogn
evas
strategi
result
directli
robust
immun
respons
includ
neutral
interfer
nonneutr
antibodi
nonnab
potenti
enhanc
viral
infect
due
presenc
antivir
ab
propens
memori
immun
system
becom
overli
influenc
earliest
immun
respons
infect
vaccin
uncertainti
develop
robust
activ
immun
strategi
virus
hiv
provid
rational
passiv
immun
strategi
employ
multipl
mab
basi
protect
therapeut
clinic
modal
varieti
viral
infect
problem
nonnab
interfer
investig
number
virus
repres
viral
evas
strategi
need
address
develop
new
vaccin
success
type
evas
strategi
also
suggest
passiv
immun
may
altern
case
hcv
broadli
crossneutr
ab
bnab
effect
direct
highli
conserv
function
critic
epitop
eg
site
among
differ
genotyp
howev
bind
hcv
bnab
may
inhibit
presenc
nonnab
bind
proxim
critic
residu
hypothesi
still
controversi
recent
experi
support
exist
interf
ab
popul
case
influenza
humor
immun
result
inactiv
receptorbind
site
ha
appear
main
mechan
influenza
neutral
addit
bnab
often
inhibit
fusion
viral
envelop
endocyt
vesicl
membran
nonnab
produc
suffici
abund
may
provid
basi
viral
escap
bnab
overal
experiment
result
suggest
nonnab
bind
epitop
ha
may
interfer
bind
nab
proxim
neutral
epitop
evid
preval
nonnab
result
viral
escap
found
sever
acut
respiratori
syndrom
coronaviru
sarscov
vaccin
strategi
direct
prevent
infect
use
sarss
viral
glycoprotein
target
strategi
proven
problemat
sinc
vaccin
coronaviru
may
result
excess
sometim
uncontrol
cellular
immun
respons
contribut
sever
diseas
case
sarscov
report
nonneutr
mab
disrupt
neutral
activ
mab
inhibit
infect
vitro
overal
result
suggest
cocktail
nmab
bind
differ
epitop
may
valid
clinic
approach
cocktail
strategi
may
especi
relev
case
hiv
cytotox
lymphocyt
neutral
ab
long
known
select
immun
escap
mutat
cours
infect
addit
inactiv
bnab
nonnab
report
antagon
propos
due
steric
hindranc
contrast
observ
addit
reactiv
involv
nonnmab
nmab
suggest
multimab
combin
support
hiv
inactiv
irrespect
individu
mab
neutral
potenc
probabl
howev
cocktail
approach
passiv
immunotherapi
hiv
need
involv
highli
crossneutr
mab
whose
affin
epitop
locat
overcom
inhibitori
effect
interf
nonnab
human
immun
system
evolv
respond
quickli
effect
infecti
challeng
long
primari
infect
resolv
immun
memori
essenti
quick
respons
capabl
avoid
much
slower
process
origin
immun
reaction
ultim
give
rise
affin
matur
antibodi
repertoir
memori
antibodi
repertoir
brought
bear
matter
day
rather
week
month
wherea
rapid
respons
essenti
prevent
repeat
infect
howev
drawback
provid
opportun
certain
virus
continu
establish
success
infect
suscept
characterist
initi
immun
respons
subsequ
inabl
memori
respons
adequ
broaden
repertoir
antibodi
face
infect
similar
mutat
strain
essenc
divers
secondari
immun
respons
compromis
domin
origin
immun
respons
first
descript
phenomenon
publish
year
ago
refer
origin
antigen
sin
oa
influenza
viru
infect
antibodi
produc
reinfect
vaccin
relat
strain
viru
appar
still
direct
first
strain
result
immun
respons
word
recal
first
influenza
viru
experienc
phenomenon
immun
system
commit
viral
variant
initi
present
continu
make
antibodi
imag
viru
even
contemporan
viru
effect
shed
imag
observ
infect
number
virus
stop
immun
system
continu
produc
highaffin
neutral
antibodi
emerg
viral
variant
entir
clear
one
potenti
consequ
oa
simpli
lack
adequ
immun
respons
mutat
viru
addit
oa
present
risk
elicit
ab
could
potenti
enhanc
diseas
sever
enhanc
viral
infect
prime
exampl
mechan
invok
dengu
viru
case
dengu
ab
deriv
initi
immun
respons
may
act
agent
exacerb
diseas
increas
cellular
uptak
virus
result
higher
viremia
phenomenon
term
antibodydepend
enhanc
ade
ade
lead
theori
explain
observ
increas
risk
sever
diseas
upon
secondari
infect
heterolog
serotyp
recent
studi
human
call
question
ade
princip
mechan
increas
diseas
risk
addit
modif
antibodi
fc
region
disrupt
antibodi
interact
fc
receptor
shown
effect
strategi
prevent
ademedi
lethal
diseas
mous
model
spite
appar
drawback
oa
shown
individu
mount
immun
respons
hiv
infect
hallmark
oa
respons
nonetheless
manag
gener
bnab
coevolv
mutat
viru
recent
studi
follow
evolut
singl
infect
individu
three
year
period
spite
propens
matur
bnab
maintain
neutral
activ
founder
viru
potenti
viral
escap
mutat
vicin
bnab
epitop
nonetheless
neutral
due
bnab
gain
neutral
breadth
affin
matur
clinic
development
immunolog
oa
therefor
complex
immun
respons
result
product
effect
neutral
ab
case
one
explan
oa
earli
induct
agspecif
b
cell
consequ
free
ab
abl
recogn
viral
escap
mutant
suffici
affin
success
compet
viral
antigen
minim
effect
b
cell
encount
viral
escap
sinc
previous
activ
b
cell
antigenspecif
ab
far
abund
b
cell
select
undergo
somat
hypermut
affin
matur
case
drive
viral
escap
benefit
phenomenon
propos
resid
adapt
immun
respons
limit
ineffect
even
patholog
antibodi
along
narrow
idiotyp
axi
henc
conserv
idiotyp
space
function
antibodi
respons
observ
ab
deriv
earli
infect
often
carri
common
idiotyp
term
propos
potenti
target
therapeut
antiidiotyp
suppress
wherea
suppress
popul
allow
higher
titr
ab
capabl
neutral
autolog
contemporan
virus
evid
suggest
bnab
develop
within
repertoir
suggest
continu
select
ab
may
fact
drive
v
region
mutat
hallmark
hiv
bnmab
six
wellcharacter
bnmab
perhap
other
express
idiotyp
addit
idiotyp
found
ab
deriv
chronic
infect
hcv
siv
potenti
method
avoid
oa
describ
includ
mask
epitop
use
cytokin
suppress
domin
b
cell
clone
import
conserv
epitop
crucial
viral
infect
propag
overst
target
immun
respons
conserv
epitop
foundat
antibodi
repertoir
contain
broadli
neutral
ab
true
immun
respons
varieti
virus
immun
respons
influenza
exampl
provid
insight
difficulti
devis
effect
vaccin
strategi
influenza
virus
best
bnmab
candid
use
therapi
prophylaxi
direct
major
antigen
site
antiinfluenza
mab
broadrang
neutral
activ
highli
diverg
isol
gener
abl
interfer
viral
fusion
process
endosom
vesicl
target
conserv
epitop
site
bnmab
poorli
induc
infect
vaccin
case
hiv
viral
infect
bnmab
influenza
virus
isol
phage
display
techniqu
directli
human
peripher
b
cell
although
robust
initi
immun
respons
hiv
infect
hallmark
diseas
infect
individu
mount
immun
respons
contain
bnab
addit
neutral
immun
respons
rare
contain
neutral
antibodi
hiv
clade
broadli
neutral
antihiv
mab
rare
impress
recent
progress
util
new
mab
discoveri
technolog
produc
varieti
bnmab
tabl
date
approxim
bnmab
repres
essenti
arsen
antiinfecti
agent
hiv
hope
singl
bnmab
ultim
found
readili
select
escap
mutat
persist
sinc
begin
hiv
antibodi
discoveri
proposit
infecti
diseas
includ
hiv
manag
use
cocktail
mab
suggest
ten
year
ago
clearli
hiv
cocktail
bnmab
would
stand
better
chanc
avoid
select
provid
protect
therapi
remaind
paper
focu
hiv
use
broadli
neutral
antihiv
mab
develop
date
progress
toward
establish
effect
multimab
approach
compar
singlemab
strategi
recent
report
one
report
order
evalu
therapeut
potenti
multipl
broadli
neutral
antibodi
establish
infect
group
human
mice
infect
isol
human
mice
use
order
minim
product
antihuman
antibodi
mice
first
treat
use
antibodi
monotherapi
evalu
five
differ
broadli
neutral
antibodi
antibodi
select
base
neutral
activ
well
breadth
clade
could
effect
neutral
vitro
addit
mab
target
differ
epitop
serum
halfliv
mab
rang
day
gener
use
monotherapi
viremia
rebound
day
concomit
appear
mutat
allow
viral
escap
mab
select
monotherapi
therefor
select
viral
escap
mutat
antibodytarget
epitop
abil
trimix
pentamix
bnmab
alter
cours
infect
evalu
contrast
monotherapi
trimix
pentamixtr
mice
remain
baselin
viral
load
entir
treatment
cours
prolong
control
infect
observ
pentamix
primarili
due
long
serum
halflif
inject
antibodi
efficaci
antibodybas
drug
may
enhanc
modif
extend
halflif
sever
fold
similar
experi
human
mice
human
multipl
mab
evalu
therapeut
efficaci
establish
infect
reveal
signific
benefit
combin
bnmab
approach
experi
broadli
neutral
antibodi
membraneproxim
extern
region
ebv
transform
b
cell
site
glycan
site
bind
site
neutral
assay
b
cell
infect
donor
resurfac
stabil
core
probe
somat
mutat
primer
probe
pyrosequenc
character
addit
antibodi
individu
effici
b
cell
immort
high
throughput
screen
mice
human
less
potent
bnmab
use
klein
et
al
studi
differ
potenc
well
inclus
two
addit
mab
make
pentamix
may
account
differ
result
mutlimab
approach
similar
combin
therapi
involv
antiretrovir
antimicrobi
anticanc
agent
sinc
circumv
select
pressur
necessarili
involv
simultan
appear
multipl
mutat
antibodi
therapi
hiv
also
offer
advantag
abl
specif
neutral
viru
recruit
compon
immun
system
result
viral
clearanc
infect
cell
elicit
effector
function
moreov
immun
complex
bnmab
may
augment
nativ
immun
far
longer
halfliv
antiretrovir
drug
multimab
microbicid
demonstr
efficaci
human
mous
model
broadli
neutral
hiv
antibodi
manufactur
mammalian
cell
combin
mabgel
complet
earli
clinic
trial
vagin
microbicid
nicotianamanufactur
see
section
multimab
consist
hsvhiv
microbicid
current
develop
mapp
biopharmaceut
nicotianamanufactur
mab
vagin
deliv
complet
small
clinic
trial
productrel
advers
event
report
julian
person
commun
sinc
intracellular
viru
would
better
protect
free
viru
advers
effect
antivir
factor
genit
environ
antivir
antibodi
cellcel
transmiss
enabl
evad
inhibit
potent
direct
antibodi
anticel
mab
import
compon
multimab
microbicid
regulatori
manufactur
challeng
multimab
strategi
recent
assum
nearli
insurmount
howev
regulatori
manufactur
procedur
shown
amen
straightforward
approach
involv
fda
guidanc
technolog
advanc
allow
reproduc
batchtobatch
potenc
well
genet
stabil
consist
phase
clinic
trial
perform
threemab
cocktail
botulinum
toxin
develop
xoma
phase
trial
perform
symphogen
involv
twomab
cocktail
crucel
twomab
rabi
cocktail
one
recent
report
productspecif
method
address
polyclon
multimab
product
focus
genet
level
use
trflp
methodolog
well
protein
level
use
ciexand
msbase
methodolog
verifi
consist
manufactur
batch
level
antigen
reactiv
method
establish
verifi
potenc
antibodi
contain
batch
product
decemb
fda
publish
draft
guidanc
industri
entitl
codevelop
two
unmarket
investig
drug
use
combin
http
wwwfdagovdrug
guidancecomplianceregulatoryinformationguidancesdefaulthtm
recommend
earlier
draft
guidanc
fda
point
consid
februari
may
direct
develop
recombin
antibodi
mixtur
multidiseas
product
eg
hsvhiv
microbicid
new
costeffici
cell
bank
manufactur
concept
multimab
product
describ
demonstr
complex
mab
composit
contain
antibodi
manufactur
highli
consist
manner
scaledup
product
process
singlebatch
manufactur
concept
repres
rel
simpl
approach
product
complex
mixtur
antibodi
integr
high
flexibl
respect
number
antibodi
design
composit
given
enorm
hiv
problem
well
cost
sensit
inher
econom
environ
hiv
therapi
urgent
need
altern
mammalian
cell
cultur
technolog
might
appropri
past
cost
product
lifethreaten
antibodybas
drug
signific
factor
determin
price
particular
drug
case
hiv
howev
shear
size
unmet
need
may
beyond
current
worldwid
manufactur
capabl
animalcellbas
product
cell
cultur
system
report
frandsen
et
al
employ
recombin
target
site
integr
individu
mab
genom
site
therebi
minim
genom
posit
effect
caus
express
cassett
mammalian
product
cell
line
expect
similar
regard
growth
product
characterist
product
system
howev
obviat
need
uniform
genet
integr
event
sinc
genom
integr
involv
gener
antibodi
produc
cell
exampl
use
transient
plant
system
express
mab
result
infect
plant
cell
agrobacterium
tumefacien
infect
perform
introduc
sever
provector
agrobacterium
deliv
viral
compon
foreign
gene
plant
cell
sens
agrobacterium
vehicl
primari
infect
system
movement
plant
wherea
ultim
recombin
function
viral
replicon
provid
celltocel
spread
amplif
high
express
none
provector
contain
plantselect
marker
eg
kanamycin
resist
select
genom
integr
express
process
consum
year
instead
agrobacteriumdeliv
provector
engin
specif
recombinas
site
codeliv
cell
counterpart
enzym
phage
integras
recombin
effici
planta
form
complet
viral
replicon
mix
codeliveri
multipl
agrobacteriumbas
vector
contain
separ
compon
viral
replicon
fast
effici
method
express
wide
rang
protein
combin
differ
element
combinatori
iter
natur
antibodi
research
well
match
approach
unlik
tradit
transgen
plant
product
mab
requir
month
year
scaleup
tabl
transient
express
technolog
prove
versatil
capabl
rapid
highyield
product
varieti
protein
abil
rapidli
produc
gram
quantiti
mab
within
day
vector
deliveri
purifi
mab
except
biopharmaceut
manufactur
dozen
mab
multipl
pathogen
produc
fashion
date
similar
produc
mammalian
cell
cultur
analyz
varieti
vitro
vivo
assay
econom
term
cost
manufactur
mab
preclin
develop
use
tradit
mammalian
cell
cultur
eg
cho
costprohibitivecgmpproduct
mab
cho
contract
manufactur
would
cost
minimum
contrast
product
plant
transient
system
gmp
estim
requir
approxim
onesixth
cost
also
anticip
signific
costsav
final
commerci
product
realiz
estim
drug
substanc
commerci
scale
cost
less
glycosyl
histor
practic
differ
mab
produc
mammalian
cell
cultur
plant
tissu
potenti
plant
glycan
affect
pharmacokinet
well
immunogen
human
transgen
nicotiana
benthamiana
line
xylosyltransferas
fucosyltransferas
activ
effect
knockedout
frequent
use
result
glycan
doubleknockout
homogen
current
fdaapprov
mab
produc
mammalian
cell
cultur
mab
tabl
produc
doubleknockout
plant
yield
glycan
without
xylos
fucos
show
significantli
enhanc
bind
fc
riiia
mediat
higher
antivir
activ
noteworthi
although
nonfucosyl
mab
rare
choand
mab
product
comparison
plantproduc
mab
larg
fraction
human
serum
igg
nonfucosyl
particularli
relev
vivo
studi
plantderiv
mab
serum
pharmacokinet
ident
mab
produc
mammalian
cell
cultur
virus
escap
mammalian
immun
system
varieti
method
evas
method
deriv
directli
characterist
immun
respons
includ
interf
nonnab
antibodydepend
enhanc
infect
attenu
immun
respons
result
limit
divers
ab
mutat
viru
compel
rational
multimab
product
serv
prevent
therapeut
drug
hiv
particular
potenti
varieti
infect
proven
recalcitr
vaccin
develop
avail
numer
broadli
neutral
mab
hiv
provid
impetu
determin
appropri
mab
combin
futur
multiab
candid
hiv
virus
may
use
transform
strategi
epitop
delin
base
neutral
fingerprint
screen
sera
character
antibodi
specif
induc
upon
infect
vaccin
addit
new
scalabl
product
system
well
favor
regulatori
environ
may
enabl
multimab
product
infecti
diseas
commerci
